{"id":45242,"date":"2026-07-27T14:19:00","date_gmt":"2026-07-27T12:19:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=8acebd7e346a8c4bd9e9c7cfe913a9bf"},"modified":"2026-07-27T14:19:00","modified_gmt":"2026-07-27T12:19:00","slug":"bonerge-lifescience-launches-clinical-study-on-equoyouth-s-equol-for-menopause-symptom-relief","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=45242","title":{"rendered":"Bonerge Lifescience Launches Clinical Study on EquoYouth\u00ae S-Equol for Menopause Symptom Relief"},"content":{"rendered":"<p>NEW YORK--(BUSINESS WIRE)--<a href=\"https:\/\/twitter.com\/hashtag\/EquoYouth?src=hash\" >#EquoYouth<\/a>--<strong>Open-label trial will evaluate a 12-week, 10 mg daily regimen of the company's high-purity S-equol ingredient in women with moderate menopausal symptoms.<\/strong><\/p><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260727525044\/en\/2860162\/5\/bonerge-logo-v2.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260727525044\/en\/2860162\/22\/bonerge-logo-v2.jpg\" \/><\/a><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260727525044\/en\/2860162\/5\/bonerge-logo-v2.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260727525044\/en\/2860162\/21\/bonerge-logo-v2.jpg\" \/><\/a><p>\nBonerge Lifescience announced a new clinical study evaluating EquoYouth\u00ae, its branded S-equol ingredient, for its potential to ease menopausal symptoms and support women through the menopausal transition \u2014 without the use of hormones.<\/p><p>\n<b>Study Design at a Glance<\/b><\/p><ul class=\"bwlistdisc\">\n<li>\n<strong>Design:<\/strong> Open-label, single-arm clinical trial<\/li>\n<li>\n<strong>Participants:<\/strong> Women aged 45\u201360 with moderate menopausal symptoms<\/li>\n<li>\n<strong>Regimen:<\/strong> 10 mg S-equol daily for 12 weeks<\/li>\n<li>\n<strong>Measures:<\/strong> Symptom severity, sleep quality, emotional well-being, cognitive function, quality of life, and safety parameters<\/li>\n<\/ul><p>\nUnlike most published S-equol research, which has centered on hot flash frequency, this design also incorporates validated sleep, mood and cognitive assessments alongside breast and endometrial ultrasound monitoring \u2014 addressing evidence gaps that remain open in the existing literature.<\/p><p>\nThis exploratory study marks the first stage of Bonerge's broader clinical research program for EquoYouth\u00ae. Once complete, the company plans to move into a randomized, double-blind, placebo-controlled trial to further confirm the ingredient's efficacy and safety profile.<\/p><p>\n<b>Why S-Equol Matters for Menopause Support<\/b><\/p><p>\nS-equol is a metabolite the body produces when gut bacteria convert soy isoflavones \u2014 but not every woman's microbiome can make that conversion. Research suggests only about a third to half of women in Western populations naturally produce equol, leaving a large group of \"non-producers\" without access to its benefits through diet alone. Direct S-equol supplementation gives these women a consistent way to access the compound, regardless of their gut microbiota composition.<\/p><p>\nOnce in the body, S-equol binds selectively to estrogen receptor beta (ER\u03b2), allowing it to support hormonal balance without acting like a hormone itself \u2014 a distinction drawing growing interest as women look for non-hormonal options for menopause support.<\/p><p>\n<b>What Earlier Research Shows<\/b><\/p><p>\nPrior published studies on 10 mg\/day S-equol supplementation have pointed to improvements in hot flashes, sleep quality, mood, and muscle discomfort, with the most pronounced effects seen among equol non-producers \u2014 the group Bonerge's new study is designed to reach.<\/p><p>\n<b>Backed by Purity and Compliance Credentials<\/b><\/p><p>\nEquoYouth\u00ae S-Equol is manufactured through a proprietary fermentation process that yields more than 99% purity by HPLC and is structurally identical to the S-equol naturally produced in the human gut. It is the first high-purity S-equol ingredient to achieve Self-Affirmed GRAS (SA-GRAS) status, and it carries FSSC 22000, Kosher, and Halal certifications.<\/p><p>\n<b>Executive Comment<\/b><\/p><p>\n\"Clinical validation is core to Bonerge's innovation strategy,\" said Allen,CEO at Bonerge Lifescience. \"Through EquoYouth\u00ae, we're building a stronger evidence base for high-quality S-equol and giving global brands an ingredient they can trust \u2014 backed by rigorous, ongoing research.\"<\/p><p>\n<b>About Bonerge Lifescience<\/b><\/p><p>\nBonerge Lifescience is a science-driven ingredient innovator building the future of health \u2014 beyond raw ingredients. The company develops clinically supported, next-generation solutions across healthy aging, women's health, sleep, and metabolic wellness, backed by proprietary technology and rigorous research. Learn more at <span class=\"bwuline\"><a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bonerge.com&amp;esheet=54577505&amp;newsitemid=20260727525044&amp;lan=en-US&amp;anchor=www.bonerge.com&amp;index=1&amp;md5=762582c75e87b0867ad7f2de5a79284a\" rel=\"nofollow\" shape=\"rect\">www.bonerge.com<\/a><\/span> .<\/p><br\/> <b>Contacts<\/b> <br\/><p>\nCecilia Yang\n<br\/><a  href=\"mailto:sales@bonerge.com\" rel=\"nofollow\" shape=\"rect\">sales@bonerge.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>NEW YORK&#8211;(BUSINESS WIRE)&#8211;#EquoYouth&#8211;Open-label trial will evaluate a 12-week, 10 mg daily regimen of the company&rsquo;s high-purity S-equol ingredient in women with moderate menopausal symptoms.<br \/>\nBonerge Lifescience announced a new clinical study evaluati&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-45242","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/45242","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45242"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/45242\/revisions"}],"predecessor-version":[{"id":45243,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/45242\/revisions\/45243"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45242"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45242"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45242"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}